Early research

PNC-27

PNC-27 (p53 HDM-2-binding domain peptide)

AI explanation

PNC-27 is a synthetic peptide that researchers developed specifically to target and kill cancer cells while leaving your healthy cells completely alone. People are interested in it because it represents a fundamentally different approach to fighting cancer — instead of the broad-brush destruction that chemotherapy causes throughout your body, PNC-27 acts like a precision-guided missile that only attacks malignant cells.

Here's how it works in your body: Cancer cells have a unique vulnerability that normal cells don't have. There's a protein called HDM-2 that's supposed to stay inside cells, but in cancer cells, this protein mistakenly appears on the outer surface of the cell membrane — like a criminal accidentally wearing a name tag. Your healthy cells never display this protein on their surface, so they remain invisible to PNC-27.

The peptide is engineered with two key parts: one section that recognizes and locks onto that HDM-2 protein like a key fitting a lock, and another section that punches holes directly through the cancer cell's outer wall. Think of it like a guided torpedo that only detonates when it finds the right target. Once PNC-27 binds to the HDM-2 on a cancer cell's surface, it creates pores that cause the cell to essentially burst and die within hours, while your normal cells remain completely untouched since they don't display the target protein.

Dosage Information

Typical Dose

Research compound — no established human dosing

Frequency

N/A

Anytime

Administration

Intravenous in research settings

Half-Life

~2 hours

estimated

Notes

Primarily a research compound. No completed human clinical trials. Several in vitro and animal studies showing selective cancer cell killing. Not a substitute for established cancer treatments.

Why this matters

Anti-cancer research peptide; limited pharmacokinetic data available.

Dose Calculator

Calculate your draw amount for an insulin syringe (U-100)

Concentration: 2,500 mcg/mL

Sign in to save your reconstitution settings for this peptide

Draw to the

10

unit mark

020406080100

Draw 10 units for your 250mcg dose of PNC-27

This calculator is for educational purposes. Always verify your calculations and consult a healthcare professional.

Where does PNC-27 sit?

See how this peptide compares across all 150 peptides in our database.

Evidence Score

0.14

Clinical trials
0.0035%
Literature
0.0830%
Community
0.0020%
Completeness
0.7515%

Compound Data

PNC-27 structure

Molecular Formula

C14H17N3O6

Molecular Weight

323.30 g/mol

IUPAC Name

2-[[5-[(4-nitrophenyl)methylamino]-5-oxopentanoyl]amino]acetic acid

PubChem CID

449243

Potential Side Effects

No human clinical dataResearch compound onlyIn vitro selectivity for cancer cells is promising but human safety unknown
Pep Talk

PNC-27 discussions

Quick Facts

Administration
Intravenous in research settings
Typical Dose
Research compound — no established human dosing
Frequency
N/A
References
0 curated + 4 from PubMed
Evidence Score
0.1 / 100

Frequently Asked Questions about PNC-27

What is PNC-27?

PNC-27 is a synthetic peptide designed to selectively kill cancer cells by targeting HDM-2 — a protein overexpressed on the membranes of cancer cells but not normal cells. PNC-27 incorporates a sequence from the p53 tumor suppressor that binds HDM-2 combined with a membrane-penetrating leader sequence. In preclinical research PNC-27 has demonstrated selective cytotoxicity against multiple cancer cell lines including breast pancreatic and leukemia cells without affecting normal cells. It represents an innovative approach to cancer peptide therapeutics exploiting a surface marker specific to malignant cells.

How does PNC-27 work?

HDM-2 (the human ortholog of MDM-2) is normally an intracellular protein that regulates p53 activity but is aberrantly expressed on the outer plasma membrane of cancer cells — a phenomenon not observed in normal healthy cells. PNC-27 is designed to bind specifically to this membrane-expressed HDM-2 creating pores in the cancer cell membrane that lead to cell lysis. The leader sequence PLFGRKP facilitates membrane insertion while the p53-derived sequence provides HDM-2 binding specificity. This mechanism differs fundamentally from conventional chemotherapy — it does not target DNA or rapidly dividing cells generally but specifically exploits the cancer-specific membrane expression of HDM-2. In cell culture studies PNC-27 induced rapid necrosis of cancer cells within hours with no toxicity to normal cells at the same concentrations.

What is the recommended dosage for PNC-27?

The typical dose is Research compound — no established human dosing. N/A. Administration: Intravenous in research settings. Primarily a research compound. No completed human clinical trials. Several in vitro and animal studies showing selective cancer cell killing. Not a substitute for established cancer treatments.

What are the side effects of PNC-27?

No human clinical data. Research compound only. In vitro selectivity for cancer cells is promising but human safety unknown

Questions reflect common community inquiries. This is not medical advice.